PR Newswire | Sep 1, 2021 08:02AM EDT

09/01 07:00 CDT

Evofem Biosciences to Participate in Investor Conferences SAN DIEGO, Sept. 1, 2021

SAN DIEGO, Sept. 1, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier will present and host one-on-one meetings at two upcoming investor conferences as follows:

H.C. Wainwright 23rd Annual Global Investment Conference

Format: Corporate presentation

Date: Monday, September 13, 2021

Time: 7:00 a.m. ET (4:00 a.m. PT)

Morgan Stanley Virtual Global Healthcare Conference

Format: Fireside chat

Date: Tuesday, September 14, 2021

Time: 12:30 - 1:00 p.m. ET (9:30 -10:00 a.m. PT)

Webcasts of both events will be available through the Events section of the Evofem website at https://evofem.investorroom.com/events for 30 days.

About Evofem BiosciencesEvofem Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company launched its first FDA-approved commercial product, Phexxi(r) (lactic acid, citric acid and potassium bitartrate), in the United States in September 2020. The Company is evaluating lead product candidate EVO100 for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeaeinfection in women in the ongoing Phase 3 clinical trial, 'EVOGUARD.' For more information, please visit evofem.com.

Phexxi(r) is a registered trademark of Evofem Biosciences, Inc.

Investor Relations ContactAmy RaskopfEvofem Biosciences, Inc.araskopf@evofem.comMobile: (917) 673-5775

View original content to download multimedia: https://www.prnewswire.com/news-releases/evofem-biosciences-to-participate-in-investor-conferences-301367047.html

SOURCE Evofem Biosciences, Inc.